|Dr. Richard Chin||Co-Founder, CEO & Director||899k||N/A||1967|
|Ms. Denise M. Bevers||Co-Founder, Sec. & Director||633.13k||N/A||1967|
|Ms. Wendy K. Wee||Chief Financial Officer||438.15k||N/A||1953|
|Dr. Hangjun Zhan||Chief Scientific Officer||432.98k||N/A||1960|
|Ms. Katja Buhrer||Chief of Staff, VP of Corp. Devel. & Investor Relations||N/A||N/A||N/A|
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
Kindred Biosciences, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 9. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 10; Compensation: 10.